Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
AVMXY's Cash to Debt is ranked higher than
91% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. AVMXY: No Debt )
Ranked among companies with meaningful Cash to Debt only.
AVMXY' s 10-Year Cash to Debt Range
Min: 7  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.78
AVMXY's Equity to Asset is ranked higher than
71% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. AVMXY: 0.78 )
Ranked among companies with meaningful Equity to Asset only.
AVMXY' s 10-Year Equity to Asset Range
Min: 0.51  Med: 0.84 Max: 0.96
Current: 0.78
0.51
0.96
Interest Coverage No Debt
AVMXY's Interest Coverage is ranked lower than
229% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 10000.00 vs. AVMXY: No Debt )
Ranked among companies with meaningful Interest Coverage only.
AVMXY' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 4
Z-Score: -16.88
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -290.58
AVMXY's Operating margin (%) is ranked lower than
87% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 3.07 vs. AVMXY: -290.58 )
Ranked among companies with meaningful Operating margin (%) only.
AVMXY' s 10-Year Operating margin (%) Range
Min: -1723.37  Med: -313.27 Max: -178.34
Current: -290.58
-1723.37
-178.34
Net-margin (%) -258.44
AVMXY's Net-margin (%) is ranked lower than
84% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.65 vs. AVMXY: -258.44 )
Ranked among companies with meaningful Net-margin (%) only.
AVMXY' s 10-Year Net-margin (%) Range
Min: -1614.68  Med: -272.97 Max: -57.58
Current: -258.44
-1614.68
-57.58
ROE (%) -178.45
AVMXY's ROE (%) is ranked lower than
90% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. AVMXY: -178.45 )
Ranked among companies with meaningful ROE (%) only.
AVMXY' s 10-Year ROE (%) Range
Min: -145.87  Med: -57.17 Max: 3.78
Current: -178.45
-145.87
3.78
ROA (%) -130.32
AVMXY's ROA (%) is ranked lower than
86% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 0.05 vs. AVMXY: -130.32 )
Ranked among companies with meaningful ROA (%) only.
AVMXY' s 10-Year ROA (%) Range
Min: -111.43  Med: -50.57 Max: 3.73
Current: -130.32
-111.43
3.73
ROC (Joel Greenblatt) (%) -641.76
AVMXY's ROC (Joel Greenblatt) (%) is ranked lower than
83% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 3.52 vs. AVMXY: -641.76 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AVMXY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -88000  Med: -1407.75 Max: 13900
Current: -641.76
-88000
13900
EBITDA Growth (3Y)(%) -12.60
AVMXY's EBITDA Growth (3Y)(%) is ranked higher than
81% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. AVMXY: -12.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AVMXY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -63.8  Med: -15.70 Max: 30.1
Current: -12.6
-63.8
30.1
EPS Growth (3Y)(%) -12.60
AVMXY's EPS Growth (3Y)(%) is ranked lower than
221% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. AVMXY: -12.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AVMXY' s 10-Year EPS Growth (3Y)(%) Range
Min: -55  Med: -17.35 Max: 29.6
Current: -12.6
-55
29.6
» AVMXY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with AVMXY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.37
AVMXY's P/B is ranked lower than
84% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 3.01 vs. AVMXY: 6.37 )
Ranked among companies with meaningful P/B only.
AVMXY' s 10-Year P/B Range
Min: 0.25  Med: 1.83 Max: 9.5
Current: 6.37
0.25
9.5
P/S 9.12
AVMXY's P/S is ranked lower than
78% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. AVMXY: 9.12 )
Ranked among companies with meaningful P/S only.
AVMXY' s 10-Year P/S Range
Min: 1.75  Med: 7.70 Max: 29
Current: 9.12
1.75
29
EV-to-EBIT -3.25
AVMXY's EV-to-EBIT is ranked lower than
242% of the 159 Companies
in the Global Medical Devices industry.

( Industry Median: 21.34 vs. AVMXY: -3.25 )
Ranked among companies with meaningful EV-to-EBIT only.
AVMXY' s 10-Year EV-to-EBIT Range
Min: -4.9  Med: -1.50 Max: 0.5
Current: -3.25
-4.9
0.5
Current Ratio 4.33
AVMXY's Current Ratio is ranked higher than
69% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 2.44 vs. AVMXY: 4.33 )
Ranked among companies with meaningful Current Ratio only.
AVMXY' s 10-Year Current Ratio Range
Min: 0.3  Med: 4.90 Max: 126.2
Current: 4.33
0.3
126.2
Quick Ratio 3.85
AVMXY's Quick Ratio is ranked higher than
72% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. AVMXY: 3.85 )
Ranked among companies with meaningful Quick Ratio only.
AVMXY' s 10-Year Quick Ratio Range
Min: 0.3  Med: 4.61 Max: 126.2
Current: 3.85
0.3
126.2
Days Inventory 329.87
AVMXY's Days Inventory is ranked lower than
93% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 129.48 vs. AVMXY: 329.87 )
Ranked among companies with meaningful Days Inventory only.
AVMXY' s 10-Year Days Inventory Range
Min: 17.1  Med: 287.06 Max: 419.94
Current: 329.87
17.1
419.94
Days Sales Outstanding 199.75
AVMXY's Days Sales Outstanding is ranked lower than
85% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 69.92 vs. AVMXY: 199.75 )
Ranked among companies with meaningful Days Sales Outstanding only.
AVMXY' s 10-Year Days Sales Outstanding Range
Min: 98.69  Med: 196.21 Max: 707.85
Current: 199.75
98.69
707.85

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.09
AVMXY's Price/Net Cash is ranked higher than
69% of the 102 Companies
in the Global Medical Devices industry.

( Industry Median: 13.32 vs. AVMXY: 9.09 )
Ranked among companies with meaningful Price/Net Cash only.
AVMXY' s 10-Year Price/Net Cash Range
Min: 1.05  Med: 3.45 Max: 25.5
Current: 9.09
1.05
25.5
Price/Net Current Asset Value 3.23
AVMXY's Price/Net Current Asset Value is ranked higher than
75% of the 207 Companies
in the Global Medical Devices industry.

( Industry Median: 6.33 vs. AVMXY: 3.23 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
AVMXY' s 10-Year Price/Net Current Asset Value Range
Min: 1  Med: 3.21 Max: 19.62
Current: 3.23
1
19.62
Price/Tangible Book 9.09
AVMXY's Price/Tangible Book is ranked lower than
69% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 4.01 vs. AVMXY: 9.09 )
Ranked among companies with meaningful Price/Tangible Book only.
AVMXY' s 10-Year Price/Tangible Book Range
Min: 0.93  Med: 2.73 Max: 18.21
Current: 9.09
0.93
18.21
Price/Median PS Value 0.61
AVMXY's Price/Median PS Value is ranked higher than
64% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. AVMXY: 0.61 )
Ranked among companies with meaningful Price/Median PS Value only.
AVMXY' s 10-Year Price/Median PS Value Range
Min: 0.43  Med: 1.63 Max: 16.45
Current: 0.61
0.43
16.45
Earnings Yield (Greenblatt) (%) -30.80
AVMXY's Earnings Yield (Greenblatt) (%) is ranked lower than
85% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.50 vs. AVMXY: -30.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AVMXY' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -30.8  Med: 444.00 Max: 87739.4
Current: -30.8
-30.8
87739.4

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:AVH.Australia, GCR.Germany,
Avita Medical Ltd. manufactures & sells regenerative & respiratory medical devices. It offers tissue-engineered products for wound & skin defects, spacers for adolescent & adults, ReCell Spray-On-Skin, Funhaler for asthma & Breath-ATech, among others.
» More Articles for AVMXY

Headlines

Articles On GuruFocus.com
Avita Medical Ltd. Patent Validated in Eleven European Countries Sep 02 2015 
Avita Medical Proposal for US Mass Casualty Preparedness Achieves High Rating Aug 31 2015 
Avita Medical Announces New Research Partnership With University of Huddersfield Aug 17 2015 
Avita Medical Announces Financial Results and Provides Corporate Update for Fourth Quarter and Fisca Jul 29 2015 
Avita Medical's ReCell(R) Recognized as Innovative Treatment for Burn Victims Jul 20 2015 
Avita Medical Data Demonstrating ReCell(R) Effectiveness in Skin Repigmentation Published in Journal Jul 06 2015 
Avita Medical Announces First Patient Enrollment in US Pivotal Study of ReCell(R) for the Treatment Jan 28 2015 
Avita Medical Provides NICE Guidance Recommendation Update Nov 12 2014 
Avita Medical Announces Receipt of $1.4 Million R&D Tax Incentive Nov 11 2014 

More From Other Websites
AVITA MEDICAL, LTD. Financials Sep 02 2015
Avita Medical Ltd. Patent Validated in Eleven European Countries Sep 02 2015
Avita Medical Proposal for US Mass Casualty Preparedness Achieves High Rating Aug 31 2015
Avita Medical Announces New Research Partnership With University of Huddersfield Aug 17 2015
Avita Medical Announces Financial Results and Provides Corporate Update for Fourth Quarter and... Jul 29 2015
Avita Medical's ReCell(R) Recognized as Innovative Treatment for Burn Victims Jul 20 2015
Avita Medical Sends Devices and Personnel to Help Treat Mass Burn Victims in Taiwan Jul 07 2015
Avita Medical Data Demonstrating ReCell(R) Effectiveness in Skin Repigmentation Published in Journal... Jul 06 2015
Avita Medical Announces Notice of Allowance of 2nd U.S. Patent Application Jun 17 2015
Avita Medical's ReCell Featured at Important US Government Symposium on Emergency Preparedness May 21 2015
Avita Medical Announces Issuance of a New U.S. Patent for ReCell(R) May 13 2015
Avita Medical Granted CE Mark for Expanded ReCell(TM) Apr 27 2015
Avita Hosts International Skin Regeneration Symposium Attended by Leading Clinicians Apr 23 2015
Avita Medical Appoints Adam Kelliher as Chief Executive Officer Apr 14 2015
Avita Medical Announces First Patient Enrollment in US Pivotal Study of ReCell(R) for the Treatment... Jan 28 2015
UPDATE - Avita Medical Provides NICE Guidance Recommendation Update Nov 12 2014
Avita Medical Provides NICE Guidance Recommendation Update Nov 12 2014
Avita Medical Announces Receipt of $1.4 Million R&D Tax Incentive Nov 11 2014
Avita Medical Secures US FDA Approval to Modify ReCell(R) Clinical Burns Trial Sep 16 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK